Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Cash Flow-to-Debt Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥76.07 Million could theoretically repay 0% of its total liabilities (CN¥1.05 Billion) in one year. Check Beijing Sun Novo Pharmaceutical Research total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Beijing Sun Novo Pharmaceutical Research Co Ltd across 9 annual periods. Also explore 688621 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Year-by-year debt coverage analysis for Beijing Sun Novo Pharmaceutical Research Co Ltd. For market capitalisation and broader financial context, see Beijing Sun Novo Pharmaceutical Research stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | CN¥93.21 Million | CN¥1.05 Billion | ▲ +145.0% |
| 2024 | 0.04x | CN¥32.02 Million | CN¥884.65 Million | ▼ -68.6% |
| 2023 | 0.12x | CN¥92.86 Million | CN¥805.76 Million | ▼ -38.5% |
| 2022 | 0.19x | CN¥103.96 Million | CN¥554.86 Million | ▲ +0.4% |
| 2021 | 0.19x | CN¥88.25 Million | CN¥473.01 Million | ▼ -43.2% |
| 2020 | 0.33x | CN¥62.99 Million | CN¥191.94 Million | ▼ -3.9% |
| 2019 | 0.34x | CN¥56.97 Million | CN¥166.76 Million | ▼ -1.1% |
| 2018 | 0.35x | CN¥44.11 Million | CN¥127.68 Million | ▲ +231.3% |
| 2017 | 0.10x | CN¥8.01 Million | CN¥76.82 Million | — |